

# Advance RESEARCH

## KAPA Sample Prep Tools advance NGS COVID-19 research

The COVID-19 pandemic has posed unprecedented challenges to millions of people raising the need for fast, robust and confident responses from the scientific community. Researchers are using KAPA Sample Preparation reagents for NGS, generating high-quality and reliable sequencing data, demonstrated through hundreds of publications. With high-performing, streamlined protocols and a holistic offering, KAPA Sample Prep reagents are becoming the solution of choice for viral genome research, viral evolution research, surveillance and host susceptibility research.

## Benefits of KAPA RNA HyperPrep Kit including KAPA HiFi DNA Polymerase

### Single-day, automation-friendly library construction

inclusive of RNA enrichment

### KAPA HiFi DNA Polymerase

offers uniform and robust library amplification

### Robust and reliable performance

across different sample types and input amounts

### Higher success rates

with lower input and degraded samples


## Selected COVID-19 research publications:

Newly identified viral genomes in pangolins with fatal disease.  
Gao WH, Lin XD, Chen YM, et al. *Virus Evol.* 2020 Apr 12;6(1):veaa020.

Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients with IBD.  
Burgueño JF, Reich A, Hazime H., et al. *Inflamm Bowel Dis.* 2020 May 12;26(6):797 – 808.

COVID-19-related Genes in Sputum Cells in Asthma. Relationship to Demographic Features and Corticosteroids.  
Peters MC, Sajuthi S, Deford P, et al. *Am J Respir Crit Care Med.* 2020 Jul 1;202(1):83 – 90.

## KAPA Sample Prep offers a breadth of solutions



## Benefits of KAPA Target Enrichment Probes

- **Proven design expertise** to access more regions from difficult targets
- **High sequencing uniformity** results in efficient coverage of more samples
- **NGS-based probe QC** for consistently reliable performance

## Spotlight on Viral Genome Targeted Sequencing

### SARS-CoV-2 Design

- **Covers 100% of the reference genome (NC\_045512)** and >99.7% of another 183 genomic sequences publicly available (GenBank)—sequencing demo data available
- **Hybrid capture may advance** characterization, surveillance and viral evolution research of divergent isolates<sup>1</sup>
- **Ordering details:** KAPA HyperExplore MAX 0.5Mb T2 from 12 rxn (IRN\* 1000004753)

Roche cat. no.	KAPA code	Description	Pack size
08098093702	KK8540	KAPA RNA HyperPrep Kit	24 rxn
08098107702	KK8541	KAPA RNA HyperPrep Kit	96 rxn
08098131702	KK8560	KAPA RNA HyperPrep with RiboErase	24 rxn
08098140702	KK8561	KAPA RNA HyperPrep with RiboErase	96 rxn
09063781001		KAPA Universal Adapter, 15 µM	960 µL
09134336001		KAPA Unique Dual-Indexed Primer Mixes, 1–96	96 rxn
09075810001		KAPA HyperCapture Reagent Kit	24 rxn
09075828001		KAPA HyperCapture Reagent Kit	96 rxn
09075780001		KAPA HyperCapture Bead Kit	24 rxn
09075798001		KAPA HyperCapture Bead Kit	96 rxn
09075879001		KAPA Probes Resuspension Buffer	1 mL
09062815001		KAPA HyperExplore MAX 0.5 Mb T2	12 rxn

\*Internal Reference Number

<sup>1</sup>Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health. 8 Jan 2021 | *COVID-19: Laboratory and diagnosis*. World Health Organization.

Published by:

**Roche Sequencing Solutions, Inc.**  
4300 Hacienda Drive  
Pleasanton, CA 94588

[sequencing.roche.com](https://sequencing.roche.com)

For Research Use Only. Not for use in diagnostic procedures. KAPA is a trademark of Roche. All other product names and trademarks are the property of their respective owners.

© 2021 Roche Sequencing Solutions, Inc. All rights reserved.

MC--06571

01/21